Overexpression of UBE2D3 gene in esophageal carcinoma cell line EC109 can influence the proliferation, migration and the sensitivity to cisplatin

Abstract

Abstract:Objective To establish a stable transfection of UBE2D3 gene in esophageal carcinoma cell line EC109, and investigate the gene overexpression effects of migration, proliferation, and the sensitivity to cisplatin in the cell line. Methods pEGFP-C1 and pEGFP-UBE2D3 plasmids were transfected into the esophageal carcinoma EC109 strain. G418 screening method was used to select stably transfected cell lines which were named as control group (NC) and overexpression group (OE), respectively. The expression efficiency was verified by RT-PCR and Western blotting, the migration was evaluated by scratch test, and the proliferation and sensitivity of cells to cisplatin were respectively determined by CCK-8 assay and half maximal inhibitory concentration (IC₅₀). Results Relative to EC109 cells, the mRNA expression of UBE2D3 of NC group was 1.010±0.590, that of OE group was 2.026±0.898. The protein expression of UBE2D3 of NC group was 0.923±0.237, OE group was 1.520±0.487, respectively. The expression of mRNA and protein level of UBE2D3 in NC was similar to that in EC109 cells(t=1.005,P＞0.05;t=1.492,P＞0.05), while that in OE was much higher than both above (t=6.682,P<0.05;t=9.150,P<0.05). The migration length of NC group was (0.161±0.062)mm at 12 h, while that of OE group was (0.052±0.007)mm(t=4.370,P<0.05). The migration length of NC group was (0.309±0.071)mm at 24 h, compared with OE group was (0.074±0.012)mm (t=3.644, P<0.05). At 12 h and 24 h, relative to NC group, the migration length of OE group was 0.236±0.051 and 0.241±0.037, respectively, which pointed out that the migration of OE was significantly lower than that of NC. For the 1st day, the proliferation of OE was 0.713±0.220 compared with that in NC (t=13.466,P<0.05), and it was 0.848±0.241 (t=27.241,P<0.05) and 0.742±0.233 (t=15.107,P<0.05) at the 2nd day and 3rd day, respectively. The IC₅₀of OE group was 0.356±0.154(t=4.326,P<0.05) relative to that of NC by disposing with cisplatin at the 1st day, it was 0.445±0.098 (t=5.870,P<0.05) and 0.481±0.096 (t=5.009,P<0.05) at the 2nd day and 3rd day, respectively. The IC50 of OE group was less than that of NC group; when deposed with 5 μg/ml cisplatin, both proliferation of OE and NC group was slower than before. At the 1st day, 2nd day and 3rd day, the proliferation of OE group was 0.606±0.283 (t=8.872,P<0.05), 0.759±0.089 (t=16.771,P<0.05) and 0.569±0.574 (t=7.885,P<0.05) relative to NC group, respectively. Moreover, relative to NC group, fraction surviving of OE group was 0.831±0.323 (t=24.226,P<0.05), 0.875±0.102 (t=33.541,P<0.05) and 0.853±0.359 (t=28.187,P<0.05) at those time points above, respectively. The proliferation of OE was slower compared with that in NC, and the inhibition efficiency of cisplatin on the proliferation of OE was more significant than that of NC. Conclusion UBE2D3 gene overexpressed in esophageal carcinoma cell line EC109 strain may result in the cell′s phenotype inhibition of the migration and proliferation and enhance its sensitivity to cisplatin.

Key words:Esophageal neoplasms,Cell movement,Cell proliferation,UBE2D3 gene

Gao Xiaojia, Yang Hui, Wu Lin, Lu Shan, He Zhongshi, Wang Wenbo, Zhou Fuxiang, Zhou Yunfeng. Overexpression of UBE2D3 gene in esophageal carcinoma cell line EC109 can influence the proliferation, migration and the sensitivity to cisplatin[J]. Journal of International Oncology, 2016, 43(3): 171-176.

References

［1］ Mueller BU, Keller S, Seipel K, et al. Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity［J］. Leuk Lymphoma, 2015, 8(21): 1-8. DOI: 10.3109/10428194.2015.1079315. ［2］ Wang W, Yang L, Hu L, et al. Inhibition of UBE2D3 expression attenuates radiosensitivity of MCF-7 human breast cancer cells by increasing hTERT expression and activity［J］. PLoS One, 2013, 8(5): e64660. DOI: 10.1371/journal.pone.0064660. ［3］ Hurley JH, Lee S, Prag G. Ubiquitinbinding domains［J］. Biochem J, 2006, 399(3): 361-372. ［4］ Okamoto Y, Ozaki T, Miyazaki K, et al. UbcH10 is the cancerrelated E2 ubiquitinconjugating enzyme［J］. Cancer Res, 2003, 63(14): 4167-4173. ［5］ Pickart CM, Eddins MJ. Ubiquitin: structures, functions, mechanisms［J］. Biochim Biophys Acta, 2004, 1695(1/3): 55-72. DOI: 10.1016/j.bbamcr.2004.09.019. ［6］ Weissman AM. Themes and variations on ubiquitylation［J］. Nat Rev Mol Cell Biol, 2001, 2(3): 169-178. DOI: 10.1038/35056563. ［7］ Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals［J］. Nat Rev Mol Cell Biol, 2005, 6(8): 599-609. DOI: 10.1038/nrm1700. ［8］ Rajendra R, Malegaonkar D, Pungaliya P, et al. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53［J］. J Biol Chem, 2004, 279(35): 36440-36444. DOI: 10.1074/jbc.C400300200. ［9］ Guan GG, Wang WB, Lei BX, et al. UBE2D3 is a positive prognostic factor and is negatively correlated with hTERT expression in eso-phageal cancer［J］. Oncol Lett, 2015, 9(4): 1567-1574. DOI: 10.3892/ol.2015.2926. ［10］ Liu YB, Gao X, Deeb D, et al. Role of telomerase in anticancer activity of pristimerin in prostate cancer cells［J］. J Exp Ther Oncol, 2015, 11(1): 41-49. ［11］ Ren JW, Li ZJ, Tu C. MiR-135 posttranscriptionally regulates FOXO1 expression and promotes cell proliferation in human malignant melanoma cells［J］. Int J Clin Exp Pathol, 2015, 8(6): 6356-6366. ［12］ Tokumoto M, Lee JY, Fujiwara Y, et al. Inorganic arsenic induces apoptosis through downregulation of Ube2d genes and p53 accumulation in rat proximal tubular cells［J］. J Toxicol Sci, 2013, 38(6): 815-820. ［13］ Li Y, Sun XX, Elferich J, et al. Monoubiquitination is critical for ovarian tumor domain-containing ubiquitin aldehyde binding protein 1 (Otub1) to suppress UbcH5 enzyme and stabilize p53 protein［J］. J Biol Chem, 2014, 289(8): 5097-5108. DOI: 10.1074/jbc.M113.533109. ［14］ Polanowska J, Martin JS, GarciaMuse T, et al. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites［J］. EMBO J, 2006, 25(10): 2178-2188. DOI: 10.1038/sj.emboj.7601102. ［15］ He X, Xiao X, Dong L, et al. MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1［J］. Tumour Biol, 2015, 36(3): 2065-2075. DOI: 10.1007/s13277-014-2814-z. ［16］ Mcginty RK, Henrici RC, Tan S. Crystal structure of the PRC1 ubiquitylation module bound to the nucleosome［J］. Nature, 2014, 514(7524): 591-596. DOI: 10.1038/nature13890.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[3]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[4]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan.Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells[J]. Journal of International Oncology, 2024, 51(3): 129-136.
[5]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[6]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[7]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer.Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition）[J]. Journal of International Oncology, 2023, 50(7): 385-397.
[8]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[9]	Ji Shiyu, Zhang Mingxin, Xie Huahong, Bai Yuan, Wang Tong.Observation on the efficacy of different stents in the treatment of patients with advanced esophageal cancer[J]. Journal of International Oncology, 2023, 50(2): 76-81.
[10]	Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng.Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy[J]. Journal of International Oncology, 2023, 50(12): 745-750.
[11]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei.Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(8): 464-472.
[12]	Lian Haiwei, Yang Shuorui, Liu Renzhong.Mechanism study on regulation of glioblastoma cell proliferation and apoptosis by sciadopitysin combined with CX-4945 through Notch1 pathway[J]. Journal of International Oncology, 2022, 49(6): 321-326.
[13]	Xia Lingling, Chen Yongshun, Li Bin, Ning Tingting, Zhang Caiyutian.Comparison of safety and efficacy between chemoradiotherapy and chemotherapy after R0 resection in pN₊esophageal squamous cell carcinoma patients[J]. Journal of International Oncology, 2022, 49(6): 334-339.
[14]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing.MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2[J]. Journal of International Oncology, 2022, 49(4): 193-198.
[15]	Ye Qian, Ling Zhi, Liu Shenxiang, Lu Guotao, Yin Xudong.Effects of sarcopenia on the clinical efficacy and prognosis of radical radiotherapy in elderly patients with esophageal cancer[J]. Journal of International Oncology, 2022, 49(4): 199-205.